Biostatistics Advance Access originally published online on October 4, 2006
Biostatistics 2007 8(3):566-575; doi:10.1093/biostatistics/kxl029
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cancer outlier differential gene expression detection
Division of Biostatistics, School of Public Health, University of Minnesota, A460 Mayo Building, MMC 303, Minneapolis, MN 55455, USA
baolin{at}biostat.umn.edu
| SUMMARY |
|---|
|
|
|---|
We study statistical methods to detect cancer genes that are over- or down-expressed in some but not all samples in a disease group. This has proven useful in cancer studies where oncogenes are activated only in a small subset of samples. We propose the outlier robust t-statistic (ORT), which is intuitively motivated from the t-statistic, the most commonly used differential gene expression detection method. Using real and simulation studies, we compare the ORT to the recently proposed cancer outlier profile analysis (Tomlins and others, 2005) and the outlier sum statistic of Tibshirani and Hastie (2006). The proposed method often has more detection power and smaller false discovery rates. Supplementary information can be found at http://www.biostat.umn.edu/
baolin/research/ort.html.
Keywords: Cancer outlier profile analysis; Differential gene expression detection; Microarray; Robust; T-statistic
| 1. INTRODUCTION |
|---|
|
|
|---|
Recently, Tomlins and others (2005)
More recently, Tibshirani and Hastie (2006)
proposed the outlier sum (OS) statistic to detect cancer gene outlier expressions. The OS and COPA are similarly defined using robust location and scale estimates of the gene expression values (more details in Section 2). Through simulation studies and applications, they have shown that the OS can perform better than the COPA, for example, having smaller false discovery rates (Benjamini and Hochberg, 1995).
In this paper, we consider the statistical methods to detect cancer genes with a subset of over- or down-expressed outlier disease samples. Many methods have been proposed to detect differentially expressed genes (see, e.g. Dudoit and others, 2002
, Troyanskaya and others, 2002
). Among them, the t-statistic is the most commonly used method. We will discuss several problems associated with the t-statistic for cancer gene outlier expression detection, which will motivate the development of the outlier robust t-statistic (ORT). We will further establish the connection of the OS, COPA, and ORT statistics to the t-statistic from a robustness consideration. Through simulation studies and applications to a public breast cancer microarray data, we empirically evaluate and compare the different outlier detection statistics.
| 2. STATISTICAL METHODS |
|---|
|
|
|---|
Consider a 2-class, for example, cancer/normal tissues, microarray data. Let
be the observed expression values for samples
and genes
. Without loss of generality, assume that the first
samples are from the normal group and the last
samples are from the cancer group, where
. In the following discussion, we assume that the outlier disease samples are overexpressed. Similar arguments will carry through to detect genes with down-expressed outlier disease samples.
The 2-sample t-test statistic for gene j is defined as
|
| (2.1) |
Here
is the pooled standard error estimate for gene j
|
|
The t-statistic is based on the assumption that all disease samples are overexpressed. While in cancer gene outlier analysis, only a subset of the disease samples are assumed to be overexpressed. Intuitively, we want to make inference only using those overexpressed samples (outliers).
In the following, we first study the recently proposed COPA method (Tomlins and others, 2005
) and the OS statistic (Tibshirani and Hastie, 2006
) for detecting cancer gene outliers. We will make some intuitive connections between these 2 outlier detection statistics and the t-statistic. The t-statistic (2.1) will be studied from a robustness (against outlier) perspective, which shows its dependence on all disease samples and the inappropriate variance estimate. We then propose an ORT to remove the "all disease samples" dependence and appropriately reduce the outlier effects on the variance.
Note that we can equivalently write the t-statistic (2.1) as
![]() | (2.2) |
where
means the sample average;
and
are the normal and disease group sample means. According to our assumption, only a subset of those disease samples (i
) is overexpressed. So the
in the numerator, which sums over all disease samples, will introduce some extra noise. Another problem is the variance estimate, which might overestimate the true value since we already know that there is a subset of outlier disease samples. The COPA and OS statistics address these 2 problems with their different approaches. They are defined as follows:
First, (robustly) standardize the data
|
| (2.3) |
where
is the median and
is the median absolute deviation of gene js expression values
|
|
where the constant
makes
approximately equal to the standard error for normally distributed random variables. Here the medians are used due to the robustness consideration.
Let
be the
percentile of the data. The COPA statistic (Tomlins and others, 2005
) is defined as the
percentile of the disease samples standardized expression values
, where the authors have used
, or 95. Note that the subtraction and scaling would not change the order of the observed values. So it is easily checked that the COPA statistic is equivalent to
|
| (2.4) |
Compared to the t-statistic, intuitively the COPA replaces the normal sample mean
by the all-sample median
, the sample standard error
by the median absolute deviation
, and the disease sample mean
by the
percentile
. Here,
can be viewed as a scaling factor to make the COPA statistics comparable across different genes.
Immediately, we can see that the COPA statistic might not be efficient, since a fixed
sample percentile is approximately equivalent to using the information from only one sample. We expect to see improved power if instead we sum over, ideally, all outlier disease samples. The OS statistic (Tibshirani and Hastie, 2006
) proposed to replace the
percentile with a sum over the outlier disease samples identified with some heuristic criterion. The OS statistic is defined as
|
|
where
is the indicator function and
calculates the interquartile range
|
|
It is commented that values greater than the limit
are defined to be outliers in the usual statistical sense.
Similarly, since the subtraction and scaling would not change the order of the observed values, it is easily checked that the OS statistic is equivalent to
|
| (2.5) |
where R is the set of "outlier disease samples" defined by the following heuristic criterion:
|
| (2.6) |
Besides the inefficiency of the COPA statistic owing to its use of a fixed
sample percentile, a second problem is that the median over all samples,
, is not quite the right statistic to replace the normal sample mean,
. It might overestimate the normal group mean owing to the contamination by disease samples if a majority of them have outlier expressions. A more intuitive and appropriate quantity might be, for example, the normal sample median.
Another problem is the median absolute deviation estimation. Since we already know that the disease and normal samples are different, it might not be the best approach to use the overall median as a common estimate for the 2 group medians. Intuitively, it might help to base our estimate on, for example, the group mediancentered expression values
|
|
where
and
are the sample medians for the normal and disease groups
|
|
An intuitive and reasonable estimate for the median absolute deviation might then be, for example,
|
| (2.7) |
which is in spirit very similar to the pooled sample variance estimate
|
|
In essence, we use the sample median to replace average, and the absolute difference to replace squared difference in order to obtain a more robust variance estimate.
Summarizing previous discussions, we propose the following ORT to detect cancer genes with overexpressed outlier disease samples
|
| (2.8) |
where
is the set of "outlier disease samples" for gene j defined by
|
| (2.9) |
Note that here we explicitly calculate the outlying measures using only the normal group samples. We use permutations to estimate the ORT's null distribution and calculate the P-values. For simplicity, we omit those constants in the statistic definition, since they would not affect the significance testing based on the permutations.
In the following, we use simulation studies and applications to a public breast cancer microarray data to empirically evaluate and compare the detection power of previously discussed 4 methods: the t-statistic, COPA, OS, and the proposed ORT.
| 3. SIMULATION STUDIES |
|---|
|
|
|---|
Simulation studies are conducted to evaluate the power of various outlier detection statistics. We also compare their false discovery rates (Benjamini and Hochberg, 1995).
Suppose we have
normal and disease samples. There are in total
genes with their expression values simulated from the standard normal distribution. The first gene contains
outlier disease samples with their expression values being added constant
. For each simulated data, we can calculate the P-value for the first gene, which is the proportion of the other (null) genes with the absolute test statistics bigger than the first gene. The P-values from the simulations can be used to estimate the true/false-positive rates, that is, the sensitivity and 1 specificity, which are then used to construct the receiver operating characteristic curve for power comparison.
Figure 1 shows the estimated true/false-positive rates based on 1000 simulations. In the extreme situation with only one outlier disease sample (
), the OS statistic performs the best, the ORT has comparable performance as the OS, and the t-statistic and COPA have almost no detection power. When increasing to
outlier disease samples, the ORT, OS, and COPA have similar power, all better than the t-statistic. For
outlier disease samples, the ORT performs the best. The detection power of both the ORT and t-statistic increases with more outlier disease samples. While the performance of the COPA and OS decreases a little bit when the outlier disease samples approach the full set (
). Overall, the ORT performs the best. It seems to be able to automatically adapt to the unknown number of outlier samples, and combine the strength of both the OS and t-statistic.
|
Next we evaluate and compare the false discovery rates of the 4 methods based on the simulation. We set
of the
genes as differentially expressed with
outlier disease samples with their expression values being added constant
. Figure 2 shows the estimated false discovery rates based on 1000 simulations for
differentially expressed genes. Similar patterns as the true/false-positive rates estimation (see Figure 1) are observed. The ORT has the overall best performance with the smallest false discovery rates.
|
Very similar patterns have been observed for
. We also did the simulation studies for
;
or
; and
. We consistently observe that the ORT has the overall best performance. Complete simulation results are available at the supplementary web site (http://www.biostat.umn.edu/
baolin/research/ort.html). In Section 4, we apply the 4 cancer gene outlier detection statistics to a public breast cancer microarray data and empirically compare their performance.
| 4. APPLICATION TO THE BREAST CANCER MICROARRAY DATA |
|---|
|
|
|---|
The breast cancer microarray data reported by West and others (2001)
Table 1 lists the confirmed breast cancerrelated genes ranked in top 25 for each outlier detection statistic. ORT identified 8 genes, 5 of them were not selected by other statistics. There were 5 genes that were missed by the ORT but identified by the others. Also listed in the table is the ranking of each gene by the 4 test statistics. The genes identified by the OS were ranked generally high by the ORT. Among those genes identified by the ORT, some were ranked low by the OS but relatively higher by the t-statistic, for example, ATM and ERBB4; while several others were ranked low by the t-statistic but relatively higher by the OS, for example, AGTR1 and CASC3. It seems likely that the proposed ORT could combine the strength of both the OS and t-statistic (see also Figures 1 and 2 in Section 3). Overall, the ORT had the best detection power.
|
Figure 3 shows the expression profiles of the 8 genes that were identified by the ORT and confirmed associated with the breast cancer in previous studies. Figure 4 shows the expression profiles of the other 5 confirmed breast cancerrelated genes that were missed by the ORT but identified by the other 3 methods. We have added some jittering to the horizontal positions to distinguish among close points. The title lists the gene names. Within the parentheses are those outlier statistics that have ranked the gene in top 25.
|
|
| 5. DISCUSSION |
|---|
|
|
|---|
Previous discussions have focused on detecting genes with overexpressed outlier disease samples. The proposed ORT can be adapted to detect cancer genes with down-expressed outlier disease samples as follows:
|
|
where
is the set of down-expressed "outlier disease samples" for gene j defined by
|
|
Similarly, here we have used the intuition that values less than the limit
are defined to be outliers in the usual statistical sense. When applied to the breast cancer microarray data to detect cancer genes with down-expressed outlier disease samples, the OS, COPA, and ORT have very similar performance. Overall, ORT has the best detection power. Complete lists of all the identified genes for different methods are available at the supplementary web site (http://www.biostat.umn.edu/
baolin/research/ort.html).
The proposed ORT is intuitively motivated from the widely used t-statistic with the robustness consideration. Compared to the COPA and OS, ORT more appropriately takes into account the difference between the normal and disease groups, for example, the proper estimation of median absolute deviation (2.7) and the use of normal group median instead of the overall median (2.8). Through simulation studies and application to public cancer microarray data, we have illustrated the competitive performance of the proposed ORT. In this paper, we have focused on comparing 2 groups. The study of multigroup comparisons will be reported in the future.
| ACKNOWLEDGMENTS |
|---|
This research was partially supported by a University of Minnesota artistry and research grant and a research grant from the Minnesota Medical Foundation. Conflict of Interest: None declared.
| REFERENCES |
|---|
|
|
|---|
-
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B (Methodological) (1995) 57:289300.[Web of Science]
Bolstad B, Irizarry R, Astrand M, Speed T. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 19:185193.
Dudoit S, Yang YH, Callow MJ, Speed TP. Statistical methods for identifying differentially expressed genes in replicated cDNA microarray experiments. Statistica Sinica (2002) 12:111139.[Web of Science]
Gentleman R, Carey V, Bates D, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, and others. Bioconductor: open software development for computational biology and bioinformatics. Genome Biology (2004) 5:R80.[CrossRef][Medline]
Tibshirani R, Hastie T. Outlier sums for differential gene expression analysis.Biostatistics. (2006) doi:10.1093/biostatistics/kxl005.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, and others. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 310:644648.
Troyanskaya OG, Garber ME, Brown PO, Botstein D, Altman RB. Nonparametric methods for identifying differentially expressed genes in microarray data. Bioinformatics (2002) 18:14541461.
West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JAJ, Marks JR, Nevins JR. Predicting the clinical status of human breast cancer by using gene expression profiles. Proceedings of the National Academy of Sciences of the United States of America (2001) 98:1146211467.
Received June 15, 2006; revised September 11, 2006; accepted for publication September 29, 2006.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
B. Andreopoulos, A. An, X. Wang, and M. Schroeder A roadmap of clustering algorithms: finding a match for a biomedical application Brief Bioinform, May 1, 2009; 10(3): 297 - 314. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ghosh and A. M. Chinnaiyan Genomic outlier profile analysis: mixture models, null hypotheses, and nonparametric estimation Biostat., January 1, 2009; 10(1): 60 - 69. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hu Cancer outlier detection based on likelihood ratio test Bioinformatics, October 1, 2008; 24(19): 2193 - 2199. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Lian MOST: detecting cancer differential gene expression Biostat., July 1, 2008; 9(3): 411 - 418. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||




) serve as the normal group, and we look for outlier samples in the lymph nodepositive (LN+) group. We have added some jittering to the horizontal positions to distinguish among close points. The title lists the gene names. Within the parentheses are those outlier statistics that have ranked the gene in top 25.


